stockrow
Monday 9 November 2026
Export ELDN’s income statement to Excel — free account
Eledon Pharmaceuticals, Inc.
ELDN- EPS
- −107.7%
- Free cash flow
- −28.0%
Quarter to June 2026, against a year earlier
2.61
0.15
+6.10%
Follow ELDN
Alert me
Eledon Pharmaceuticals, Inc. (ELDN) P/E ratio
Eledon Pharmaceuticals, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 19.6× (July 2025) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|
Against its own ten years
Low 0.0×
High 19.6×
Ten-year median
0.0×
Current reading's percentile
96
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| ELDN Eledon Pharmaceuticals, Inc. | n/m |
| IFRX InflaRx N.V. compare | n/m |
| IKT Inhibikase Therapeutics, Inc. compare | n/m |
| DRUG Bright Minds Biosciences Inc. compare | n/m |
| ARTV Artiva Biotherapeutics, Inc. compare | n/m |
| RNAC Cartesian Therapeutics, Inc. compare | n/m |
| SLGL Sol-Gel Technologies Ltd. compare | n/m |
| PALI Palisade Bio, Inc. compare | 1.7× |
| PLX Protalix BioTherapeutics, Inc. compare | 10.6× |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)